Postiglione Ilaria, Chiaviello Angela, Barra Federica, Roscetto Emanuela, Soriano Amata A, Catania Maria Rosaria, Palumbo Giuseppe, Pierantoni Giovanna Maria
Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples 80131, Italy.
Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council (CNR), Naples 80131, Italy.
Int J Mol Sci. 2015 Aug 28;16(9):20375-91. doi: 10.3390/ijms160920375.
Photofrin/photodynamic therapy (PDT) at sub-lethal doses induced a transient stall in proteasome activity in surviving A549 (p53(+/+)) and H1299 (p53(-/-)) cells as indicated by the time-dependent decline/recovery of chymotrypsin-like activity. Indeed, within 3 h of incubation, Photofrin invaded the cytoplasm and localized preferentially within the mitochondria. Its light activation determined a decrease in mitochondrial membrane potential and a reversible arrest in proteasomal activity. A similar result is obtained by treating cells with Antimycin and Rotenone, indicating, as a common denominator of this effect, the ATP decrease. Both inhibitors, however, were more toxic to cells as the recovery of proteasomal activity was incomplete. We evaluated whether combining PDT (which is a treatment for killing tumor cells, per se, and inducing proteasome arrest in the surviving ones) with Bortezomib doses capable of sustaining the stall would protract the arrest with sufficient time to induce apoptosis in remaining cells. The evaluation of the mitochondrial membrane depolarization, residual proteasome and mitochondrial enzymatic activities, colony-forming capabilities, and changes in protein expression profiles in A549 and H1299 cells under a combined therapeutic regimen gave results consistent with our hypothesis.
亚致死剂量的卟吩姆钠/光动力疗法(PDT)在存活的A549(p53(+/+))和H1299(p53(-/-))细胞中诱导了蛋白酶体活性的短暂停滞,这通过胰凝乳蛋白酶样活性随时间的下降/恢复得以体现。实际上,在孵育3小时内,卟吩姆钠侵入细胞质并优先定位于线粒体中。其光激活导致线粒体膜电位降低以及蛋白酶体活性的可逆性停滞。用抗霉素和鱼藤酮处理细胞也得到了类似结果,这表明作为这种效应的共同特征,ATP减少。然而,这两种抑制剂对细胞的毒性更大,因为蛋白酶体活性的恢复并不完全。我们评估了将PDT(其本身是一种杀死肿瘤细胞并在存活细胞中诱导蛋白酶体停滞的治疗方法)与能够维持停滞状态的硼替佐米剂量联合使用,是否会延长停滞时间,以便有足够时间诱导剩余细胞凋亡。在联合治疗方案下,对A549和H1299细胞的线粒体膜去极化、残余蛋白酶体和线粒体酶活性、集落形成能力以及蛋白质表达谱变化进行评估,结果与我们的假设一致。